Skip to main content
OpenTrials
Completed

NCT Number: NCT03882112

Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects

Primary objective

- To evaluate food effect on the pharmacokinetics (PK) of a single oral dose of HIP1601 in healthy subjects under fed or fasting condition.

Secondary objectives

* To explore food effect on the pharmacodynamics (PD) of single oral dose of HIP1601 in healthy subjects under fed or fasting condition. * To evaluate the safety of single oral dose of HIP1601 in healthy subjects under fed or fasting condition.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

19 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Seoul National University Biomedical Research Institute

Seoul, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male/Female healthy volunteers in the age between 19 and 50 years old.
  • Body mass index (BMI) in the range of 19 to 28 kg/m2 and weight 55.0kg to 90.0kg.
  • Helicobacter pylori (H. Pylori) negative.
  • After fully hearing and understanding the details of this clinical trial, Subjects who have willingness to sign of informed consent before the screening.
  • Subject who are eligible from physical examination, clinical laboratory test by investigators judgment.

Exclusion criteria

  • Gastrointestinal disorders (gastrointestinal ulcers, gastritis, stomach cramps, gastro-esophageal reflux disease, Crohn's disease or chronic pancreatitis) or gastrointestinal surgery (except for simple cecal or hernia surgery) which may affect the safety and pharmacokinetic evaluation of test drug.
  • Subjects who have a history of hypersensitivity or clinically significant hypersensitivity to esomeprazole or the same component or other drugs (aspirin, antibiotics, etc.).
  • Blood serum aspartate aminotransferase and alanine aminotransferase exceed 1.5 times the upper limit of normal range from screening laboratory results before randomization.
  • Subject who continues to drink (21 units / week, 1 unit = 10 g of pure alcohol) within a month before the screening visit or who cannot abstain during the hospital stay.
  • Heavy smoker (>10 cigarettes/day).

Treatment and study plan

HIP1601 40mg

Drug

Single dosing of HIP1601 40mg, orally

Other names: HIP1601

Primary outcomes

  1. Cmax

    Time frame: Blood sampling during 24 hours after administration

    Maximum observed concentration after dose

  2. Area Under the plasma concentration versus time Curve(AUC)last

    Time frame: Blood sampling during 24 hours after administration

    Area under the plasma concentration versus time curve from dosing to the last quantifiable concentration

Secondary outcomes

  1. Tmax

    Time frame: Blood sampling during 24 hours after administration

    Time of Cmax over the time span specified

  2. AUCinf

    Time frame: Blood sampling during 24 hours after administration

    Area under the plasma concentration versus time curve from the time of dosing to time extrapolated to infinitely

  3. t1/2

    Time frame: Blood sampling during 24 hours after administration

    Terminal half-life

  4. Clearance/F

    Time frame: Blood sampling during 24 hours after administration

    Apparent total body clearance after extravascular administration, calculated as Dose/AUCinf

  5. Vd/F

    Time frame: Blood sampling during 24 hours after administration

    Apparent volume of distribution after extravascular administration, calculated as Dose/(λzㆍAUCinf)

Other outcomes

  1. Integrated gastric acidity for 24-hour

    Time frame: Blood sampling during 24 hours after administration

    Percent decrease from baseline in integrated gastric acidity for 24-hour interval after dose

  2. Duration of time intra-gastric pH 4.0 or higher

    Time frame: Blood sampling during 24 hours after administration

    Percent of time with intra-gastric pH greater than 4.0 for 24-hour interval after dose

  3. Median pH

    Time frame: Blood sampling during 24 hours after administration

    Median intra-gastric pH for 24-hour interval after dose

  4. Integrated gastric acidity by time interval

    Time frame: Blood sampling during 24 hours after administration

    Percent decrease from baseline in integrated gastric acidity after dose by time intervals

Sponsors and collaborators

Lead sponsor

Hanmi Pharmaceutical Company Limited

Industry

Registry information

Official study title

A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics and Pharmacodynamics of HIP1601 40 mg in Healthy Volunteers

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 20, 2019
Registry last updated
Sep 6, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.